<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04770389</url>
  </required_header>
  <id_info>
    <org_study_id>TA-8995-303</org_study_id>
    <nct_id>NCT04770389</nct_id>
  </id_info>
  <brief_title>Randomized Study of Obicetrapib in Combination With Ezetimibe</brief_title>
  <acronym>OCEAN</acronym>
  <official_title>A Placebo-Controlled, Double-Blind, Randomized Phase 2 Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe in Participants With Mild Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NewAmsterdam Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NewAmsterdam Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a placebo-controlled, double-blind, randomized, phase 2 study in&#xD;
      participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of&#xD;
      obicetrapib and ezetimibe combination therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a placebo-controlled, double-blind, randomized, phase 2 study in&#xD;
      participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of&#xD;
      obicetrapib and ezetimibe combination therapy. The screening period for this study will take&#xD;
      up to 2 weeks. Following the screening period, eligible patients will be randomized to&#xD;
      placebo, 5 mg obicetrapib + 10 mg ezetimibe; 5 mg obicetrapib + placebo ezetimibe; or placebo&#xD;
      obicetrapib + 10 mg ezetimibe for an 8 week treatment period. After the treatment period,&#xD;
      patients will continue for a 4 week safety follow-up and a 8 week PK follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">May 7, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Placebo-Controlled, Double-Blind, Randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>placebo tablet made to resemble active</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>obicetrapib in combination with ezetimibe compared to placebo on LDL-C</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percent change from baseline in LDL-C</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>obicetrapib monotherapy compared to placebo on LDL-C</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percent change from baseline in LDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>obicetrapib in combination with ezetimibe compared to placebo on ApoB</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percent change from baseline in ApoB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>obicetrapib monotherapy compared to placebo on Apo-B</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percent change from baseline in Apo-B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>obicetrapib in combination with ezetimibe compared to ezetimibe monotherapy on LDL-C</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percent change from baseline in LDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>obicetrapib monotherapy compared to ezetimibe monotherapy on LDL-C</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percent change from baseline in LDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ezetimibe monotherapy compared to placebo on LDL-C</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percent change from baseline in LDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>obicetrapib in combination with ezetimibe compared to ezetimibe monotherapy on ApoB</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percent change from baseline in ApoB</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Dyslipidemias</condition>
  <condition>High Cholesterol</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo obicetrapib + placebo ezetimibe; once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg obicetrapib + 10 mg ezetimibe; once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obicetrapib monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg obicetrapib + placebo ezetimibe; once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo obicetrapib + 10 mg ezetimibe; once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obicetrapib 5mg</intervention_name>
    <description>tablet</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_label>Obicetrapib monotherapy</arm_group_label>
    <other_name>CETP inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe 10mg</intervention_name>
    <description>tablet</description>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_label>Ezetimibe monotherapy</arm_group_label>
    <other_name>Antihyperlipidemic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Understanding of the study procedures, willingness to adhere to the study schedules&#xD;
             and diet, and agreement to participate in the study by giving written informed consent&#xD;
             prior to Screening procedures&#xD;
&#xD;
          -  Men or women 18 to 70 years of age, inclusive&#xD;
&#xD;
          -  Women may be enrolled if all 3 of the following criteria are met:&#xD;
&#xD;
          -  They are not pregnant;&#xD;
&#xD;
          -  They are not breastfeeding; and&#xD;
&#xD;
          -  They do not plan on becoming pregnant during the study&#xD;
&#xD;
          -  Women of childbearing potential must have a negative urine pregnancy test at the&#xD;
             Screening Visit.&#xD;
&#xD;
          -  Women of childbearing potential must agree to use an effective method of avoiding&#xD;
             pregnancy from the Screening Visit to 90 days after the last visit. Men whose partners&#xD;
             are of childbearing potential must agree to use an effective method of avoiding&#xD;
             pregnancy from the Screening Visit to 90 days after the last visit.&#xD;
&#xD;
          -  Fasting LDL-C levels &gt;2.5 mmol/L (&gt;100 mg/dL) and &lt;4.5 mmol/L (&lt;175 mg/dL) and TG&#xD;
             levels &lt;4.5 mmol/L (&lt;400 mg/dL) (Visit 1) and&#xD;
&#xD;
          -  Willingness to maintain a stable diet and physical activity level throughout the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index &gt;= 40 kg/m2&#xD;
&#xD;
          -  Participation in another clinical study involving an investigational or marketed drug&#xD;
             within 30 days prior to the Screening Visit&#xD;
&#xD;
          -  Currently taking any lipid-altering therapy&#xD;
&#xD;
          -  Any clinical manifestation of atherosclerotic CVD or any evidence of ischemic coronary&#xD;
             disease present on the 12-lead ECG at the Screening Visit&#xD;
&#xD;
          -  Diagnosis of type 1 or type 2 diabetes mellitus; or HbA1c &gt;= 6.5% at the Screening&#xD;
             visit if no prior diagnosis of diabetes mellitus&#xD;
&#xD;
          -  Uncontrolled hypertension ie, sitting systolic blood pressure &gt;160 mmHg and/or sitting&#xD;
             diastolic blood pressure &gt;90 mmHg taken as the average of triplicate measurements.&#xD;
&#xD;
        One retest will be allowed, at which point if the retest result is no longer exclusionary,&#xD;
        the participant may be randomized&#xD;
&#xD;
          -  Active muscle disease or persistent creatine kinase concentration &gt;3 x the upper limit&#xD;
             of normal (ULN). One retest will be allowed after 1 week to verify the result, at&#xD;
             which point if the retest result is no longer exclusionary, the participant may be&#xD;
             randomized&#xD;
&#xD;
          -  History of torsades de pointes&#xD;
&#xD;
          -  Estimated glomerular filtration rate &lt;60 mL/min calculated using the Chronic Kidney&#xD;
             Disease Epidemiology Collaboration equation&#xD;
&#xD;
          -  Hepatic dysfunction as evidenced by any laboratory abnormality as follows: gamma-&#xD;
             glutamyl transferase, alanine aminotransferase, or aspartate aminotransferase &gt;2 x&#xD;
             ULN, or total bilirubin &gt;1.5 x ULN&#xD;
&#xD;
          -  Anemia, defined as hemoglobin concentration &lt;11 g/dL for males and hemoglobin&#xD;
             concentration &lt;9 g/dL for females&#xD;
&#xD;
          -  History of malignancy within the past 5 years, with the exception of non-melanoma skin&#xD;
             cancers&#xD;
&#xD;
          -  Evidence of any other clinically significant non-cardiac disease or condition that, in&#xD;
             the opinion of the Investigator, would preclude participation in the study&#xD;
&#xD;
          -  Known ezetimibe or CETP inhibitor allergy or intolerance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trials Research</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Premier Healthcare Research LLC</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juno Research, LLC - Medical Center Office</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Thomsonplein</name>
      <address>
        <city>Den Haag</city>
        <zip>2565 KN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huisartsen Praktijk Rambharose</name>
      <address>
        <city>Den Haag</city>
        <zip>2572 GM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huisartsen Praktijk A.M.N. Zijtregto</name>
      <address>
        <city>Rotterdam</city>
        <zip>3037 AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huisartsen Praktijk van Soerland</name>
      <address>
        <city>Rotterdam</city>
        <zip>3067 GJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huisartsen Praktijk Broekman</name>
      <address>
        <city>Zwijndrecht</city>
        <zip>3333 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokters van Nederhoven</name>
      <address>
        <city>Zwijndrecht</city>
        <zip>3334 SB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obicetrapib</keyword>
  <keyword>statin</keyword>
  <keyword>LDL-C</keyword>
  <keyword>cholesterol</keyword>
  <keyword>atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Hypolipidemic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

